trending Market Intelligence /marketintelligence/en/news-insights/trending/348el_ymz0pi8mffr8qxpq2 content esgSubNav
In This List

Rosetta Genomics, Genoptix merger terminated

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Rosetta Genomics, Genoptix merger terminated

Rosetta Genomics Ltd. terminated its planned merger with Genoptix Inc. after failing to secure majority shareholder approval for the deal.

The Israeli genomic diagnostics company said that about 47% of its shareholders voted, with about 66% in favor of the deal.

Following the deal termination, Rosetta will reimburse $750,000 of Genoptix's expenses in three installments as provided by the merger agreement.

Genoptix has indicated that it remains interested in pursuing alternative options to consummate a transaction with Rosetta.